AbbVie Inc.'s third-quarter revenue from its immunology portfolio was $5.79 billion, a 14.8% increase year over year. That result included revenue from AbbVie's Humira medication of $5.14 billion, a figure that rose 4.1% year over year. "AbbVie Logs 3Q Sales Growth on Higher Immunology, Oncology Results," published at 8:07 a.m. ET, incorrectly said that immunology revenue increased 4.1%, to $5.14 billion.
(END) Dow Jones Newswires